Inhibrx Biosciences (INBX) Interest Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Interest Expenses data on file, last reported at $3.2 million in Q4 2025.

• Interest Expenses for Q4 2025 came in at $3.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $12.2 million (down 9.6% YoY), and the FY2025 annual result was $12.2 million, down 9.6% from the prior year.
• Interest Expenses held at $3.2 million in Q4 2025 per INBX's latest filing, from $3.2 million in the prior quarter.
• Over five years, Interest Expenses peaked at $8.2 million in Q4 2023 and troughed at $2.7 million in Q1 2025.
• A 3-year average of $5.6 million and a median of $5.4 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 32.18% in 2024, then plunged 66.92% in 2025.
• A 3-year view of Interest Expenses shows it stood at $8.2 million in 2023, then sank by 34.8% to $5.4 million in 2024, then slumped by 40.59% to $3.2 million in 2025.
• Business Quant data shows INBX's Interest Expenses at $3.2 million in Q4 2025, $3.2 million in Q3 2025, and $3.1 million in Q2 2025.